Abstract: The present invention provides an improved process for the preparation of alpha form of imatinib mesylate with (long needle) and ?-crystal form (small needle) in a consistent manner and novel alpha crystal forms of imatinib mesylate. The present invention in particular provides a reproducible and efficient process. In particular the present invention provides a efficient process which gives higher yields and consistent results.

Abstract: The present invention provides a process for the preparation of a tetrazine derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein R1 represents a hydrogen atom, a straight or branched C1-C6 alkyl group, C2-C6 alkenyl group or C2-C6 alkynyl group, which C1-C6 alkyl group, C2-C6 alkenyl group and C2-C6 alkynyl group is unsubstituted or substituted with 1, 2 or 3 substituents selected from halogen atoms, straight or branched C1-C4 alkoxy groups, C1-C4 alkylthio groups, C1-C4 alkylsulphinyl groups, C1-C4 alkylsulphonyl groups and phenyl groups, which phenyl groups are unsubstituted or substituted with one or more substituents selected from C1-C4 alkyl groups, C1-C4 alkoxy groups and nitro groups; or R1 represents a C3-C8 cycloalkyl group; and R2 represents a group of formula —(C?O)NR3R4, wherein R3 and R4 are independently selected from hydrogen atoms, C1-C4 alkyl groups, C2-C4 alkenyl groups and C3-C8 cycloalkyl groups, which process comprises: i) providing a compound N of formula (III

Abstract: Orally administrable acid stable anti-ulcer benzimidazole derivatives which are polymer based. The process of preparation comprises condensing a benzimidazole with a biocompatible partially orally biodegradable synthetic cross linked polymer in aqueous medium at 5-80° C. and pH 4-11 under inert atmosphere. The weight percentage of benzimidazole with respect to the polymeric benzimidazole is 1-50. The reaction mixture is cooled and the product is isolated and dried at 25-45° C. There is also provided a formulation of the polymeric benzimidazoles in combination with pharmaceutically acceptable excipients.

Abstract: Orally administrable acid stable anti-ulcer benzimidazole derivatives which are polymer based. The process of preparation comprises condensing a benzimidazole with a biocompatible partially orally biodegradable synthetic cross linked polymer in aqueous medium at 5-80° C. and pH 4-11 under inert atmosphere. The weight percentage of benzimidazole with respect to the polymeric benzimidazole is 1-50. The reaction mixture is cooled and the product is isolated and dried at 25-45° C. There is also provided a formulation of the polymeric benzimidazoles in combination with pharmaceutically acceptable excipients.

Abstract: Orally administrable acid stable anti-ulcer benzimidazole derivatives which are polymer based. The process of preparation comprises condensing a benzimidazole with a biocompatible partially orally biodegradable synthetic cross linked polymer in aqueous medium at 5°-80° C. and pH 4-11 under inert atmosphere. The weight percentage of benzimidazole with respect to the polymeric benzimidazole is 1-50. The reaction mixture is cooled and the product is isolated and dried at 25°-45° C. There is also provided a formulation of the polymeric benzimidazoles in combination with pharmaceutically acceptable excipients.